Forte Biosciences (FBRX) Research & Development (2016 - 2026)

Forte Biosciences (FBRX) has 11 years of Research & Development data on file, last reported at $20.3 million in Q1 2026.

• On a quarterly basis, Research & Development rose 62.02% year-over-year to $20.3 million in Q1 2026; TTM through Mar 2026 was $65.4 million, a 126.13% increase from a year earlier, with the FY2025 full-year figure at $57.6 million, up 178.3% from the prior year.
• Research & Development for Q1 2026 stood at $20.3 million, down from $21.6 million in the prior quarter.
• Over the last five years, Research & Development for FBRX reached as high as $21.6 million in Q4 2025 and fell as low as $693000.0 in Q1 2022.
• Historically, Research & Development has averaged $7.4 million across 5 years, with a median of $5.6 million in 2024.
• Across the five-year window, Research & Development plunged 79.14% in 2022 and jumped 590.76% in 2023, its largest moves.
• Year by year, Research & Development stood at $2.5 million in 2022, then surged by 43.37% to $3.6 million in 2023, then surged by 42.42% to $5.1 million in 2024, then jumped by 324.92% to $21.6 million in 2025, then declined by 5.86% to $20.3 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $20.3 million in Q1 2026, $21.6 million in Q4 2025, and $15.0 million in Q3 2025.